Efficacy and Safety of ATL-962 in Obese Diabetics
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such...
Brief Summary
Official Title: “Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat”
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Detailed Clinical Trial Description
Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.
In this study patients with Type II diabetes who are clinically obese will receive ATL-962 at one of three dose levels, or placebo, or orlistat (another lipase inhibitor). The study will investigate the amount of weight lost after 12 weeks' treatment and will compare the safety and tolerability profile of ATL-962 and orlistat.
Intervention(s) in this Clinical Trial
- Drug: ATL-962
- Drug: Orlistat
Outcome Measures for this Clinical Trial
Primary Measures
- Absolute weight loss compared to baseline
Secondary Measures
- Proportion of patients achieving 5% or 10% weight loss
- Changes in waist circumference
- Changes in lipid profiles
- Changes in markers of diabetes
- Incidence of gastrointestinal adverse effects
- Changes in other safety parameters
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Type II diabetes
- Body mass index 28-45kg/m2
- HbA1c 6%-10%
Exclusion Criteria:
- Significant weight loss in the previous 3 months
- Weight gain during the run-in period
- Other serious systemic conditions, except controlled hypertension, mild asthma, and primary hypothyroidism
- History of GI disorders
- Previous surgery for weight loss
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 65 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Alizyme Industry
Overall Clinical Trial Officials and Contacts
Peter Kopelman Principal Investigator Queen Mary's School of Medicine & Dentistry, London, UK
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00156897
Study ID Number: ATL-962/175/CL
ClinicalTrials.gov Identifier: NCT00156897
Health Authority: United Kingdom: Department of Health
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00156897
